The US Drug Enforcement Administration ( DEA ) has proposed new rules that could have a significant impact on the legality of delta-9 THC extracted from cannabis. With these regulations, medications containing delta-9 THC would be eligible for approval by the US Food and Drug Administration ( FDA ) by moving cannabis from a schedule I to a schedule III substance. This change would make cannabis a restricted drug rather than a narcotic without any accepted medical applications.
Almost 4 million Americans currently use medical marijuana officially at the condition level, which conflicts with national laws. The common legislation at the state level raises questions about the bonuses for pharmaceutical companies to obtain FDA approval for cannabis-based medications.
Igor Grant, director of the Center for Medicinal Cannabis Research at the University of California, San Diego, notes that state legislation has outpaced national legislation, probably deterring medical expense in cannabis. Jahan Marcu, writer of” Cannabis Innovations”, stock this skepticism, suggesting that the organized market for cannabis and cannabis materials makes FDA approval less appealing.
The purchase of hemp outside the national regulatory method has been a trend for decades, leading to a market flooded with thousands of cannabis– and cannabis-based products. Due to this competition, it is difficult for pharmaceutical firms to gain from brand-new, FDA-approved cannabis products. Grant raises questions about the economic justification for big pharmaceutical companies entering this sector despite the clinics ‘ lower prices.
However, some pharmaceutical firms are exploring health hemp. In 2022, Pfizer acquired Arena Pharmaceuticals, which conducts studies on clinical cannabis. Professor Peter Grinspoon, writer of” Seeing Through the Smoke” and a professor at Harvard Medical School, explains the complex relationship between hemp advocates and pharmaceutical companies. First, pharmaceutical companies resisted hemp legalization, fearing competitors with home-grown cannabis. Some businesses have opted to invest in hemp projects because of the financial effects of legislation.
Developing FDA-approved medication is expensive and time-consuming, usually requiring hundreds of millions of dollars and many phases of testing. Despite these challenges, Music Pharmaceuticals properly developed Epidiolex, a natural form of CBD approved for unique seizures. Unlike delta-9 THC, CBD is officially authorized under the 2018 Farm Bill. Music Pharmaceuticals is working to expand Epidiolex’s authorization to other countries, possible increasing profitability.
Marcu suggests that pharmaceutical companies may have a better chance of succeeding if they can find cannabis-based medications approved in several nations, particularly those where it is less readily available. This global perspective might increase the value of medical cannabis analysis.
If medical companies decide that medical cannabis study is not successful, the plant’s complete medical potential properly remain undiscovered. Ingrinspoon insists that the FDA approval process is crucial for improving and maximizing the efficacy of drugs. Cannabinoids that are specific formulations could have significant medical advantages and provide specific treatments for a variety of ailments. The partnership between pharmaceutical companies and research into health cannabis may lead to novel and potent cannabis-based treatments.
